Independent reporting on the science, medicine, and business of health optimization — GLP-1s, peptides, longevity, and the telehealth economy.https://wellnesswire.com/en-us© Wellness Wirehttps://wellnesswire.com/articles/what-we-still-dont-know-about-a-decade-on-semaglutide/https://wellnesswire.com/articles/what-we-still-dont-know-about-a-decade-on-semaglutide/Ten years of published data. Hundreds of thousands of patient-years of exposure. And yet the questions that matter most to the people on these drugs — what happens to muscle, to bone density, to the brain, to the hunger set point when you stop — have not been answered by anyone with an incentive to ask them.Mon, 20 Apr 2026 00:00:00 GMTGLP-1Dr. Sarah Chen-Whitfieldhttps://wellnesswire.com/articles/the-glp-1-era-has-just-begun/https://wellnesswire.com/articles/the-glp-1-era-has-just-begun/A class of drugs built for diabetes has quietly become the largest pharmacological intervention in modern weight management. The next decade will decide whether that story ends in medicine — or in marketing.Tue, 21 Apr 2026 00:00:00 GMTGLP-1Anya Raohttps://wellnesswire.com/articles/why-your-brain-is-the-real-target-of-glp-1-drugs/https://wellnesswire.com/articles/why-your-brain-is-the-real-target-of-glp-1-drugs/The "gut hormone" framing misses the point. Four neuroscientists walk through where these drugs actually work — and why the hypothalamus matters more than the gut.Tue, 21 Apr 2026 00:00:00 GMTGLP-1Anya Raohttps://wellnesswire.com/articles/inside-the-trial-that-made-tirzepatide-the-new-standard/https://wellnesswire.com/articles/inside-the-trial-that-made-tirzepatide-the-new-standard/SURMOUNT-5 compared tirzepatide head-to-head with semaglutide for the first time. The read-through reshaped prescribing overnight. Here is what actually happened in the data.Tue, 21 Apr 2026 00:00:00 GMTTirzepatideMarcus Holthttps://wellnesswire.com/articles/semaglutides-second-act-is-about-the-heart/https://wellnesswire.com/articles/semaglutides-second-act-is-about-the-heart/SELECT showed a 20% reduction in major cardiovascular events. Cardiologists are rewriting secondary-prevention playbooks in real time. The obesity angle may end up being the smaller story.Tue, 21 Apr 2026 00:00:00 GMTSemaglutideDr. Priya Chenhttps://wellnesswire.com/articles/bpc-157-is-everywhere-and-almost-nowhere-in-the-literature/https://wellnesswire.com/articles/bpc-157-is-everywhere-and-almost-nowhere-in-the-literature/The internet's favorite "healing peptide" has a robust mechanism story and almost zero human trial data. We went looking for what the published evidence actually supports — and what it does not.Mon, 20 Apr 2026 00:00:00 GMTPeptidesJonas Weberhttps://wellnesswire.com/articles/rapamycin-is-still-the-most-interesting-drug-in-longevity/https://wellnesswire.com/articles/rapamycin-is-still-the-most-interesting-drug-in-longevity/Year three of the first long-term healthy-adults trial just published. The results are smaller than the evangelists hoped and larger than the skeptics predicted. Both camps have some explaining to do.Mon, 20 Apr 2026 00:00:00 GMTLongevityDr. David Ikembahttps://wellnesswire.com/articles/sermorelin-is-the-quiet-comeback-story-of-growth-hormone/https://wellnesswire.com/articles/sermorelin-is-the-quiet-comeback-story-of-growth-hormone/A 1990s growth-hormone-releasing peptide is having a second life in longevity clinics. The mechanism is real. The clinical case is mixed. The market does not seem to care.Mon, 20 Apr 2026 00:00:00 GMTPeptidesRhea Suleimanhttps://wellnesswire.com/articles/what-a-continuous-glucose-monitor-actually-tells-you/https://wellnesswire.com/articles/what-a-continuous-glucose-monitor-actually-tells-you/CGMs have escaped the diabetes clinic and become a wellness product. The signal-to-noise is worse than the marketing implies. We put three on healthy subjects for ninety days.Sun, 19 Apr 2026 00:00:00 GMTMetabolic HealthDr. Priya Chenhttps://wellnesswire.com/articles/the-telehealth-boom-was-built-on-a-drug-shortage/https://wellnesswire.com/articles/the-telehealth-boom-was-built-on-a-drug-shortage/Ro, Hims, Found, Mochi — the platforms grew by arbitraging a specific FDA exemption on compounded semaglutide. That window is closing. The playbook that follows will define the next five years of the industry.Sun, 19 Apr 2026 00:00:00 GMTThe Telehealth EconomyAnya Raohttps://wellnesswire.com/articles/the-quiet-reason-glp-1s-keep-working-after-you-stop-eating/https://wellnesswire.com/articles/the-quiet-reason-glp-1s-keep-working-after-you-stop-eating/The satiety story is the marketing story. The actual mechanism is weirder, slower, and harder to reproduce with lifestyle interventions — which is why the drugs work where discipline fails.Sat, 18 Apr 2026 00:00:00 GMTGLP-1Anya Raohttps://wellnesswire.com/articles/the-case-against-switching-to-tirzepatide-too-soon/https://wellnesswire.com/articles/the-case-against-switching-to-tirzepatide-too-soon/Head-to-head data favors tirzepatide on most endpoints. That does not mean every patient on semaglutide should switch. Three scenarios where the numbers lie.Sat, 18 Apr 2026 00:00:00 GMTTirzepatideMarcus Holthttps://wellnesswire.com/articles/compounded-glp-1s-explained-without-the-spin/https://wellnesswire.com/articles/compounded-glp-1s-explained-without-the-spin/The FDA shortage exemption, the 503A/503B distinction, the patent landscape — everything patients ask their doctor about, rendered without the telehealth-marketing gloss or the pharma-lobbyist scare story.Fri, 17 Apr 2026 00:00:00 GMTCompounded MedicineJonas Weberhttps://wellnesswire.com/articles/next-wave-weight-loss-peptides-in-trials/https://wellnesswire.com/articles/next-wave-weight-loss-peptides-in-trials/Retatrutide, amylin agonists, orforglipron. The incretin pipeline has five drugs readers should know about, and the reason to care is that the clinical profile is meaningfully different from semaglutide and tirzepatide.Fri, 17 Apr 2026 00:00:00 GMTPeptidesDr. Priya Chenhttps://wellnesswire.com/articles/biological-age-tests-are-selling-certainty/https://wellnesswire.com/articles/biological-age-tests-are-selling-certainty/Horvath, GrimAge, PhenoAge — the three major epigenetic clocks are impressive science and underwhelming products. The reason comes down to what a clock can and cannot do for an individual.Thu, 16 Apr 2026 00:00:00 GMTLongevityDr. David Ikembahttps://wellnesswire.com/articles/tirzepatide-is-doing-something-semaglutide-cannot/https://wellnesswire.com/articles/tirzepatide-is-doing-something-semaglutide-cannot/The weight-loss advantage is real. The mechanism explanation is more interesting: the GIP axis matters in ways the field spent a decade dismissing. Here is what changed.Thu, 16 Apr 2026 00:00:00 GMTTirzepatideMarcus Holthttps://wellnesswire.com/articles/nad-therapy-breakthrough-or-placebo/https://wellnesswire.com/articles/nad-therapy-breakthrough-or-placebo/IV clinics charge $500 a session. The science is real. The clinical trials are not. The gap between "biologically plausible" and "clinically proven" is exactly where this industry lives — and patients are paying for the uncertainty.Wed, 15 Apr 2026 00:00:00 GMTNAD+Dr. Priya Chenhttps://wellnesswire.com/articles/fda-drew-a-line-compounding-industry-stepped-over-it/https://wellnesswire.com/articles/fda-drew-a-line-compounding-industry-stepped-over-it/A May 2026 enforcement deadline was supposed to end the compounded-GLP-1 gray market. Two weeks in, the workarounds are already operational, the pharmacies are still shipping, and the Texas and Louisiana lawsuits are reshaping the legal theory.Wed, 15 Apr 2026 00:00:00 GMTCompounded MedicineJonas Weberhttps://wellnesswire.com/articles/the-hunger-set-point-theory-revisited/https://wellnesswire.com/articles/the-hunger-set-point-theory-revisited/The body-weight set point is either the most useful concept in obesity medicine or the most misused. A careful look at what forty years of evidence does and does not support.Tue, 14 Apr 2026 00:00:00 GMTLongevityDr. Priya Chenhttps://wellnesswire.com/articles/dosing-re-dosing-and-the-maintenance-question/https://wellnesswire.com/articles/dosing-re-dosing-and-the-maintenance-question/What happens to patients who taper, stop, and restart? The observational data is messier than the trials and more relevant to real-world practice. Here is what a clinician should actually expect.Tue, 14 Apr 2026 00:00:00 GMTGLP-1Dr. Priya Chen